Meeting
2022 ASCO Annual Meeting
innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors.
Authors
Xiuning Le
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Xiuning Le , Benedito A. Carneiro , David S. Hong , Ariel E. Birnbaum , Matthew H. Taylor , Shetal Arvind Patel , William Nassib William Jr., Bokai Wang , Francisco Beca , Shweta Jain , Ibrahima Soumaoro , Lara Dunn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03485209
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS6100)
DOI
10.1200/JCO.2022.40.16_suppl.TPS6100
Abstract #
TPS6100
Poster Bd #
90a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).
First Author: Edward B. Garon
Poster
2019 ASCO Annual Meeting
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
First Author: Salma K. Jabbour
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.